Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar's Logo
Create Free Account
You are currently offline. Some features of the site may not work correctly.
National Institutes of Health
Semantic Scholar uses AI to extract papers important to this topic.
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas.
Corpus ID: 209418238
BACKGROUND The discovery of effective therapeutic options for treating metastatic poorly differentiated neuroendocrine carcinoma…
Preclinical Study on Radiosensitization by Combining a Novel Drug Lipotecan With Radiation Therapy in Hepatocellular Carcinoma
Corpus ID: 78922459
Abstract A89: A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388 (Lipotecan®), administered intravenously to patients with advanced solid tumors.
Corpus ID: 84034224
Introduction: TLC388 (Lipotecan) is a potent Topoisomerase-1 inhibitor and it can disrupt both Sonic Hedgehog and HIF1-α pathways…
A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors.
Journal of clinical oncology : official journal…
Corpus ID: 8389494
e13618 Background: The phase I first-in-human study of TLC388 (Lipotecan) examined the MTD, safety, anti-tumor activity and…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE